2022-502672-23-00招募中1 期
A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies
Prelude Therapeutics Inc.10 个研究点 分布在 4 个国家目标入组 109 人开始时间: 2023年9月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 109
- 试验地点
- 10
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Medical Lead
Scientific
Prelude Therapeutics Inc.
研究点 (10)
Loading locations...
相似试验
尚未招募
1 期
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian CancerNCT07273396Seoul National University Hospital53
招募中
3 期
177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus2022-502154-13-00Grupo Espanol De Tumores Neuroendocrinos135
招募中
1 期
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid TumorsCancerNCT07269899Sun Yat-sen University12
尚未招募
1 期
Bladder Perfusion of Plasma-Activated Saline for Bladder CancerNCT07272603Qilu Hospital of Shandong University5
招募中
2 期
Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHLNCT07271121King Hussein Cancer Center26